Market Outlook
By 2032, the U.S. Orthotic Devices Market is projected to reach approximately USD 2.64 billion, expanding at a CAGR of 6.79% during the forecast period 2027–2032. The market stands at USD 1.78 billion in 2026, following historical expansion from approximately USD 1.42 billion in 2023 to USD 1.66 billion in 2025. Values throughout this report are expressed in USD billions.
The forecast trajectory places the market at approximately USD 1.90 billion in 2027, USD 2.03 billion in 2028, USD 2.17 billion in 2029, USD 2.31 billion in 2030, USD 2.47 billion in 2031, and USD 2.64 billion by 2032. Growth is being supported by the combined impact of population aging, osteoarthritis, sports and occupational injuries, post-operative orthopedic rehabilitation, neurological mobility impairment, diabetes-related lower-extremity complications, and a broader clinical preference for conservative musculoskeletal management before surgical escalation.
Orthotic devices occupy an important position between medication, physical rehabilitation, and orthopedic surgery. Unlike implanted orthopedic devices, orthoses can be deployed across acute injury, chronic disease, postoperative recovery, mobility assistance, deformity correction, and preventive care. The U.S. market therefore includes both relatively high-volume, lower-price products such as ankle supports, wrist braces, and elastic knee supports and higher-value clinical systems such as custom knee unloading braces, ankle-foot orthoses, thoracolumbosacral orthoses, scoliosis braces, stance-control orthoses, and digitally fabricated patient-specific devices.
The underlying clinical addressable population is substantial. More than one-fifth of U.S. adults have diagnosed arthritis, around 33 million adults live with osteoarthritis, and arthritis prevalence among adults aged 65 and older approaches one-half of the population. The U.S. population aged 65 years and above has already exceeded 61 million people, creating a durable patient pool for joint instability, gait impairment, degenerative knee disease, spinal conditions, fall-risk management, and post-surgical bracing.
Demand is also reinforced by acute injury. Ankle sprains remain among the most common musculoskeletal injuries treated in the United States, with millions occurring annually across clinical and non-clinical settings. Knee ligament injuries, shoulder instability, wrist and hand injuries, fractures, and postoperative immobilization create recurring demand across orthopedics, emergency care, sports medicine, rehabilitation, and ambulatory surgery.
From a procurement perspective, the U.S. orthotic devices market is becoming less dependent on basic product availability and more dependent on fit accuracy, clinical documentation, patient compliance, reimbursement predictability, digital workflow compatibility, turnaround time, and measurable functional improvement. Suppliers able to combine clinically differentiated products with fitting support, reimbursement expertise, inventory efficiency, and digital customization are increasingly better positioned than vendors competing primarily on unit price.
Introduction
According to the U.S. Orthotic Devices Market Report, orthotic devices comprise externally applied medical devices used to support, stabilize, protect, align, unload, immobilize, or improve the function of a body segment or joint. The market covered in this report includes knee orthoses, ankle-foot orthoses, spinal orthoses, upper-extremity orthoses, foot orthoses, hip orthoses, pediatric bracing systems, and related custom-fabricated or prefabricated devices. Prosthetic limbs, implanted orthopedic devices, mobility aids, stand-alone compression garments, and general consumer wellness products without meaningful orthotic functionality are excluded.
The United States provides an unusually attractive commercial environment for orthotic-device manufacturers because musculoskeletal care is delivered across multiple channels. Orthopedic surgeons, physiatrists, podiatrists, neurologists, primary-care physicians, physical therapists, certified orthotists, hospital discharge teams, ambulatory surgical centers, sports-medicine practices, and durable medical equipment suppliers can all influence product selection. This creates a fragmented purchasing environment but also expands the number of clinical entry points available to manufacturers.
The market is strongly linked to chronic musculoskeletal disease. Diagnosed arthritis affects 21.3% of U.S. adults, while approximately 33 million U.S. adults have osteoarthritis. Among people aged 65 years and above, diagnosed arthritis affects approximately 47.8%. These figures are commercially important because knee OA braces, spinal supports, foot orthoses, wrist and hand supports, and other conservative technologies are often used before or alongside injections, medication, physical therapy, and surgery.
Population aging reinforces this demand. The U.S. population aged 65 and older reached approximately 61.2 million in 2024, representing 18% of the population, and the demographic continues to expand. Older patients have higher rates of arthritis, balance impairment, spinal degeneration, neurological weakness, fracture, and joint replacement. More than 14 million adults aged 65 and older report falling each year, creating an additional clinical rationale for lower-limb stabilization, ankle-foot orthoses, rehabilitation bracing, and mobility-focused orthotic intervention.
The market is equally relevant to younger patients. Sports participation, recreational activity, occupational exposure, ligament injury, ankle sprains, scoliosis, cerebral palsy, neuromuscular disorders, and postoperative recovery create demand across pediatric, adolescent, working-age, and athletic populations. This broad demographic reach makes orthotics less dependent on a single disease category than many other medical-device segments.
Historical market expansion from USD 1.42 billion in 2023 to USD 1.53 billion in 2024 and USD 1.66 billion in 2025 reflects increasing outpatient orthopedic activity, higher utilization of advanced braces, recovery in elective orthopedic procedures, wider availability of custom-fitted products, growing digital fabrication capabilities, and greater consumer familiarity with non-surgical musculoskeletal care.
Between 2027 and 2032, the competitive center of gravity will increasingly shift toward patient-specific devices, rapid digital fitting, lighter materials, connected rehabilitation, outpatient dispensing, and products that combine clinical effectiveness with easier reimbursement documentation. A brace that performs well clinically but creates fitting complexity, returns, documentation burden, or poor patient adherence is increasingly disadvantaged in the U.S. market.
Key Market Drivers: What’s Fueling the U.S. Orthotic Devices Market Boom?
The first major growth driver is the scale of degenerative musculoskeletal disease. Osteoarthritis commonly affects the knees, hips, hands, and spine, making it highly relevant to the orthotic-device market. Approximately 33 million U.S. adults live with osteoarthritis. For manufacturers, knee OA represents one of the highest-value conservative-care opportunities because unloading braces can redistribute joint forces and support mobility in selected patients who are attempting to delay surgery or remain active despite degenerative disease.
The second driver is rapid population aging. Adults aged 65 years and older now represent a structurally larger proportion of the U.S. population, and this demographic has substantially higher arthritis prevalence. Older age also increases exposure to gait instability, foot drop, spinal degeneration, fractures, joint replacement, and neurological disease. Orthotic manufacturers therefore participate not only in orthopedic treatment but also in mobility preservation and independent living.
A third driver is the size of the injury and rehabilitation population. Acute ankle sprains remain among the country’s most common musculoskeletal injuries. Updated national emergency-department research covering 2010–2024 identified approximately 7.4 million ankle sprain presentations during the period, while broader clinical literature indicates that annual U.S. ankle-sprain incidence is materially higher when primary-care, sports, self-treated, and non-emergency cases are included. Knee ligament injuries, shoulder injuries, fractures, tendon injuries, and wrist trauma further expand the recurring brace-utilization pool.
A fourth driver is the migration of orthopedic procedures toward outpatient care. Ambulatory surgery centers and hospital outpatient departments increasingly manage arthroscopy, ligament repair, selected fracture procedures, foot and ankle surgery, hand procedures, and joint-replacement pathways. Earlier discharge transfers more recovery responsibility to the patient and caregiver. Postoperative orthoses that can be fitted rapidly, provide controlled range of motion, and simplify home recovery become particularly valuable in this environment.
A fifth driver is the growing importance of conservative care economics. Orthotic devices generally carry far lower episode costs than surgery and can be integrated with physical therapy, analgesic management, injection therapy, or rehabilitation. Payers and providers therefore have incentives to use properly indicated bracing where it can preserve function, protect healing tissue, reduce pain, improve gait, or delay escalation to more invasive treatment.
The sixth driver is Medicare and commercial reimbursement. Orthoses fall within established U.S. reimbursement pathways, including Medicare’s DMEPOS framework for covered leg, arm, back, and neck braces. Medicare generally pays 80% of the applicable allowed amount for covered DMEPOS after relevant beneficiary obligations, subject to medical-necessity, coding, documentation, supplier, and policy requirements. This creates a large reimbursed market while simultaneously making coding quality and documentation capability critical competitive differentiators.
Compliance intensity itself is reshaping the market. Medicare reported a 35.2% improper-payment rate for lower-limb orthoses in the 2024 reporting period, associated with USD 91.2 million in projected improper payments. Lumbar-sacral orthoses recorded a 54.4% improper-payment rate and USD 47.8 million in projected improper payments. These figures do not imply fraudulent use; they demonstrate how frequently incomplete documentation or other payment requirements create reimbursement risk. Manufacturers and distributors that help providers standardize medical-necessity documentation, coding, proof of delivery, and fitting workflows can therefore create value beyond the physical product.
Innovation in Focus: How Manufacturers Are Raising the Bar?
Innovation in the U.S. orthotic devices industry is increasingly centered on improving the relationship between biomechanical performance and patient adherence. Historically, an orthosis could achieve its mechanical objective but fail commercially or clinically because the patient found it heavy, hot, restrictive, difficult to apply, or conspicuous. Manufacturers are addressing this problem through lighter polymers, carbon composites, breathable structures, low-profile hinges, anatomically contoured frames, improved padding systems, and easier adjustment.
Digital scanning is changing custom orthotics manufacturing. Traditional plaster casting and manual measurement remain clinically relevant, but optical scanning and digital capture allow providers to acquire patient anatomy more quickly, transfer files electronically, and reduce some of the variability associated with manual fabrication. Digital workflows can also shorten the time between evaluation and final delivery, an important issue in busy orthopedic, podiatric, and orthotics practices.
Additive manufacturing is emerging as a complementary production method, particularly for patient-specific foot orthoses, pediatric systems, selected ankle-foot orthoses, and complex geometries. The strongest commercial opportunity is not simply 3D printing for its own sake. It is using digital design to create repeatable correction, reduce weight, improve ventilation, and enable efficient remanufacturing when the patient’s prescription or anatomy changes.
Advanced knee bracing remains a major innovation area. Osteoarthritis unloading systems are moving toward lower-profile designs and simplified adjustment, while postoperative braces increasingly combine rapid sizing with controlled range-of-motion mechanisms. Functional sports braces continue to compete on frame weight, hinge performance, suspension, comfort, and the ability to maintain position during movement.
Pediatric spinal bracing is another important innovation category. In June 2026, Enovis introduced the DonJoy Spinamic Hybrid Scoliosis Brace in the United States, combining rigid corrective elements with a more adjustable design and ten off-the-shelf sizes. The strategic importance of this type of product is workflow-related: a device that allows evaluation, fitting, and adjustment within fewer visits can reduce fabrication delay while potentially improving patient acceptance.
Smart orthotic concepts are also gaining interest. Pressure sensors, gait analytics, activity monitoring, adherence tracking, and digitally connected rehabilitation systems could allow clinicians to evaluate whether a device is being worn correctly and whether functional performance is improving. Adoption will depend on whether these features change clinical decisions or reimbursement rather than simply adding technology cost.
The regulatory profile supports a relatively active innovation environment for many conventional orthoses. Several external knee, ankle, hip, and limb orthosis categories are regulated by the FDA as Class I devices, and many are exempt from premarket notification requirements. This lowers certain development barriers compared with high-risk implantable devices, although manufacturers remain responsible for applicable quality, labeling, complaint, registration, and general regulatory requirements.
Segmentation Insights
The U.S. Orthotic Devices Market is segmented on the basis of product type, device configuration, application, end user, distribution channel, and region.
- By Product Type
Knee Orthoses
Knee orthoses represent the largest product category, accounting for approximately 33.5% of the 2026 market, equivalent to USD 0.60 billion. The category includes functional ligament braces, postoperative range-of-motion braces, osteoarthritis unloading braces, patellofemoral supports, immobilizers, and soft knee supports.
Demand spans osteoarthritis, ACL and MCL injury, meniscal procedures, joint instability, sports medicine, postoperative rehabilitation, and preventive use. Knee orthoses benefit from a particularly wide price spectrum, ranging from basic supports to custom unloading systems. Through 2032, value growth will increasingly favor anatomically fitted OA braces, lighter functional braces, and postoperative systems that reduce fitting complexity.
Ankle-Foot Orthoses and Lower-Limb Orthoses
Ankle-foot and related lower-limb orthoses account for approximately 23.0% of the market, or USD 0.41 billion in 2026. Products include ankle braces, walking supports, AFOs for foot drop, custom molded AFOs, carbon-composite systems, and selected knee-ankle-foot orthoses.
The segment benefits from sports injuries, neurological gait dysfunction, stroke rehabilitation, cerebral palsy, multiple sclerosis, peripheral neuropathy, trauma, and postoperative care. Medicare’s substantial lower-limb orthosis claims volume demonstrates the size of the reimbursed clinical market. Digital fabrication and carbon-composite AFOs are likely to lift average selling value in complex gait applications.
Spinal Orthoses
Spinal orthoses represent approximately 17.0% of 2026 revenue, or USD 0.30 billion. This segment includes lumbar-sacral orthoses, thoracolumbosacral orthoses, cervical systems, hyperextension braces, postoperative spinal supports, and scoliosis bracing.
Demand is linked to spinal surgery, vertebral fracture, scoliosis, chronic back disorders, trauma, and stabilization protocols. Because reimbursement documentation for lumbar-sacral devices receives substantial payer scrutiny, vendors with disciplined clinical and coding support have an advantage over suppliers relying on high-volume commodity distribution.
Upper-Extremity Orthoses
Upper-extremity orthoses account for approximately 12.0% of the market, equal to USD 0.21 billion in 2026. The category includes wrist, hand, finger, elbow, shoulder, and arm orthoses.
Demand is generated by fractures, carpal tunnel syndrome, tendon injuries, postoperative shoulder immobilization, stroke rehabilitation, arthritis, and occupational strain. Growth will be supported by outpatient hand surgery, shoulder procedures, rehabilitation, and wider availability of anatomically contoured prefabricated solutions.
Foot Orthoses and Custom Inserts
Foot orthoses and clinically oriented custom inserts account for approximately 10.0% of market value, or USD 0.18 billion in 2026. The segment includes functional foot orthoses, accommodative devices, specialty inserts, and selected diabetic-foot applications where orthotic functionality is central.
Podiatric care, plantar mechanical disorders, diabetic foot-risk management, gait correction, pediatric deformity, and sports medicine support demand. The U.S. diabetes burden is especially relevant: more than 31 million diagnosed cases are reflected in national state-profile data, while broader national surveillance indicates roughly one in eight Americans has diabetes. Foot complications and lower-extremity disease therefore remain important long-term demand drivers.
Hip and Other Specialized Orthoses
Hip and other specialized orthoses account for approximately 4.5% of 2026 revenue, or USD 0.08 billion. This category includes hip stabilization devices, abduction systems, specialized pediatric orthoses, and niche neuromuscular bracing.
Although smaller in value, the segment can command attractive pricing because many products are prescribed for complex postoperative, congenital, pediatric, or neurological indications requiring specialized fitting.
- By Device Configuration
Prefabricated and Off-the-Shelf Orthoses
Prefabricated and off-the-shelf systems represent approximately 51% of the 2026 market, or USD 0.91 billion. Their leadership reflects rapid availability, standardized sizing, relatively predictable manufacturing economics, and broad use across orthopedic clinics, hospitals, emergency departments, retail channels, and home recovery.
OTS knee, ankle, wrist, shoulder, and back braces generate particularly high unit volumes. Competition is intense, making fit systems, clinician familiarity, channel relationships, and inventory efficiency critical.
Custom-Fitted Orthoses
Custom-fitted products account for approximately 28% of the market, or USD 0.50 billion in 2026. These products begin with a standardized device but require meaningful clinical adjustment to the individual patient.
The segment is particularly important in higher-value knee, spinal, and lower-limb bracing. Manufacturers benefit when product architecture allows a clinician or orthotist to achieve accurate alignment without lengthy modification.
Custom-Fabricated Orthoses
Custom-fabricated systems represent approximately 21% of the market, equal to USD 0.37 billion in 2026, and are expected to gain strategic importance through 2032.
Custom AFOs, pediatric systems, complex spinal orthoses, and patient-specific foot devices are increasingly benefiting from digital scanning, CAD-based design, advanced polymers, carbon composites, and additive manufacturing. The segment carries greater labor and workflow intensity but also supports higher differentiation and lower commoditization.
- By Application
Sports and Ligament Injuries
Sports and ligament injuries constitute approximately 28% of market demand, corresponding to USD 0.50 billion in 2026. Knee ligament braces, ankle stabilization systems, shoulder supports, and wrist or elbow products form the core of this category.
The market is sustained by organized athletics, recreational exercise, adolescent sports participation, occupational activity, and recurrent injury. Ankle injuries alone create a large recurring treatment population, while ACL, MCL, patellar, shoulder, and wrist conditions add higher-value functional bracing.
Osteoarthritis and Degenerative Musculoskeletal Disorders
Osteoarthritis and related degenerative conditions represent approximately 26% of the market, or USD 0.46 billion in 2026. Approximately 33 million U.S. adults have OA, while overall diagnosed arthritis affects more than one-fifth of adults.
Knee unloading braces are the most commercially important devices in this category, but spinal, hand, wrist, foot, and ankle orthoses also support chronic disease management. Growth will be particularly strong where braces can help patients maintain activity or delay surgical intervention.
Post-Operative and Trauma Rehabilitation
Postoperative and trauma applications account for approximately 19% of 2026 revenue, or USD 0.34 billion. Range-of-motion knee braces, shoulder immobilizers, spinal supports, ankle systems, hand splints, fracture orthoses, and hip devices support this category.
The shift toward same-day orthopedic surgery is strategically important because patients require reliable support immediately after discharge. Hospitals and ASCs increasingly favor devices that can be stocked efficiently, fitted rapidly, and transferred into home rehabilitation with minimal complexity.
Neuromuscular and Gait Disorders
Neuromuscular and gait-management applications represent approximately 12% of the market, equivalent to USD 0.21 billion in 2026. Key indications include foot drop, stroke, cerebral palsy, multiple sclerosis, peripheral nerve injury, muscular weakness, and other gait abnormalities.
This is one of the most innovation-sensitive segments because device weight, energy return, stance control, alignment, and patient-specific geometry materially affect function. Advanced AFOs and digitally designed orthoses are expected to capture a growing portion of market value.
Congenital and Pediatric Conditions
Congenital and pediatric applications account for approximately 8% of 2026 revenue, or USD 0.14 billion. Scoliosis, cerebral palsy, developmental abnormalities, clubfoot-related care, gait disorders, and pediatric neuromuscular conditions create recurring demand.
Children frequently require device replacement as they grow, producing different utilization economics than adult orthotics. Comfort, adjustability, adherence, cosmetic acceptability, and rapid refitting are commercially important.
Preventive Support and Chronic Pain Management
Preventive and pain-management applications account for approximately 7% of the market, or USD 0.12 billion in 2026. Products are used for repetitive strain, occupational support, recurrent ankle instability, sports prevention, back support, and episodic musculoskeletal pain.
The U.S. chronic-pain population is large: 24.3% of adults reported chronic pain in 2023, while 8.5% reported high-impact chronic pain that frequently restricted work or life activities. Not all of this population requires orthoses, but it indicates the scale of conservative-care demand.
- By End User
Orthopedic, Podiatry and Orthotics & Prosthetics Clinics
Specialist outpatient clinics represent approximately 36% of the 2026 market, or USD 0.64 billion. These settings lead the market because they combine diagnosis, prescribing, fitting, adjustment, and follow-up.
Certified orthotists and specialized orthopedic practices are especially influential in custom-fabricated AFOs, scoliosis systems, advanced knee braces, and other devices where biomechanical alignment matters.
Hospitals and Ambulatory Surgical Centers
Hospitals and ASCs account for approximately 25% of revenue, or USD 0.45 billion in 2026. Their demand is concentrated in trauma, postoperative care, emergency orthopedics, spine surgery, joint procedures, and discharge protocols.
Procurement increasingly favors standardized product families that reduce SKU complexity while covering multiple sizes and indications. Vendor service levels, staff training, replenishment, and reimbursement documentation can influence contract awards as much as product cost.
Physical Therapy and Rehabilitation Centers
Rehabilitation providers represent approximately 15% of market value, equal to USD 0.27 billion in 2026. Orthoses are frequently integrated with strengthening, gait training, range-of-motion restoration, and neuromuscular rehabilitation.
This channel is likely to become increasingly influential as orthopedic care shifts from episodic intervention toward functional recovery and measurable patient outcomes.
Homecare and Consumer Settings
Homecare and patient-directed settings represent approximately 15% of market value, or USD 0.27 billion in 2026. Growth is supported by outpatient recovery, telehealth, chronic-condition management, retail availability, and online purchasing.
Clinical-grade brands have an advantage where patients seek products that provide greater confidence than generic consumer supports, particularly after receiving an initial physician or therapist recommendation.
Sports Medicine and Athletic Facilities
Sports medicine centers, athletic programs, and performance-oriented facilities account for approximately 9% of the market, or USD 0.16 billion in 2026. Functional knee braces, ankle stabilizers, wrist supports, and return-to-sport products dominate this segment.
Although smaller by total revenue, this channel has high brand visibility and can influence broader consumer perceptions of brace performance.
- By Distribution Channel
Clinical DME and Orthotics Suppliers
Clinical DME and specialist orthotic suppliers account for approximately 38% of the 2026 market, or USD 0.68 billion. Their role is particularly important for reimbursed, physician-prescribed, custom-fitted, and custom-fabricated products.
Supplier accreditation, payer contracting, HCPCS coding expertise, documentation management, proof-of-delivery processes, and patient fitting create meaningful barriers to entry.
Hospital and Clinic Dispensing
Direct dispensing through hospitals, orthopedic groups, surgery centers, and physician practices represents approximately 27% of revenue, equal to USD 0.48 billion in 2026.
Providers favor this channel when immediate access improves care coordination or prevents the patient from navigating a separate fulfillment process after surgery or injury.
Retail and Specialty Stores
Retail and specialty outlets account for approximately 18% of the market, or USD 0.32 billion in 2026. Products are concentrated in elastic and semi-rigid knee, ankle, wrist, elbow, and back supports.
Retail growth is constrained by commoditization but benefits from immediate availability and consumer awareness.
E-Commerce and Direct-to-Consumer Channels
E-commerce and direct channels represent approximately 17% of market value, or USD 0.30 billion in 2026, and are among the fastest-growing distribution pathways.
Digital channels are strongest for standardized braces but are expanding into higher-value products as companies provide online sizing, clinician-assisted fitting, telehealth support, and replacement purchasing. By 2032, e-commerce could exceed one-fifth of the market if manufacturers preserve clinical credibility while improving digital fulfillment.
Regional Insights: Where the Market is Growing Fastest
The U.S. Orthotic Devices Market is geographically segmented into the South, West, Northeast, and Midwest. Regional performance differs materially based on population scale, age distribution, obesity, arthritis burden, diabetes prevalence, sports participation, orthopedic procedure volumes, provider density, Medicare exposure, and access to specialized orthotics services.
The South is the largest regional market, while the West is positioned for the strongest technology-led growth through 2032. The Northeast remains a high-value specialist market with strong academic and rehabilitation infrastructure, while the Midwest provides a substantial base of orthopedic, rehabilitation, and chronic musculoskeletal demand.
South
The South represents approximately 36% of U.S. orthotic-device revenue, equivalent to USD 0.64 billion in 2026, making it the country’s largest regional market. Under the four-region Census framework, the South includes Delaware, Maryland, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida, Kentucky, Tennessee, Mississippi, Alabama, Oklahoma, Texas, Arkansas, and Louisiana, with the District of Columbia forming part of the regional provider ecosystem.
The South has several structural drivers simultaneously supporting orthotic demand. It combines rapid population growth in major states, a large Medicare population, elevated obesity and diabetes burden, high musculoskeletal disease prevalence, extensive orthopedic and rehabilitation networks, and significant rural populations requiring conservative mobility solutions.
CDC data show that the South has some of the country’s highest physical-inactivity and obesity levels. Regional adult obesity prevalence was approximately 34.5% in 2024, while several Southern states exceeded 35%. Mississippi and West Virginia were among the states with adult obesity prevalence at or above 40%. Obesity increases mechanical loading on the knee, ankle, and foot and is associated with a higher burden of osteoarthritis and mobility impairment, strengthening demand for lower-extremity orthoses.
Texas is the most strategically important state market in the region. Its population exceeded 31.7 million in 2025, making it the second-largest state nationally. Dallas-Fort Worth, Houston, San Antonio, and Austin support large orthopedic systems, sports-medicine practices, rehabilitation networks, children’s hospitals, and DME suppliers. The combination of population growth and significant suburban expansion provides an attractive environment for both clinical orthotics and direct-to-consumer brace sales.
Florida is another critical orthotic market, with more than 23.4 million residents in 2025 and an unusually large older population. The state is especially attractive for knee osteoarthritis bracing, spinal supports, AFOs, fall-risk management, postoperative orthopedic rehabilitation, and Medicare-linked DMEPOS products. Approximately 5.1 million Florida residents were aged 65 or older in 2024, creating one of the largest absolute senior-care markets in the country.
Georgia and North Carolina, with populations above 11 million each, are becoming increasingly important because of migration, health-system expansion, and strong urban orthopedic markets around Atlanta, Charlotte, Raleigh-Durham, and other metropolitan areas. Sports medicine, pediatric orthotics, postoperative bracing, and advanced rehabilitation are important opportunities.
Virginia and Maryland benefit from high healthcare spending, major hospital systems, federal and military healthcare infrastructure, and dense specialist networks. These markets can support premium custom and digitally fabricated products where reimbursement and clinical evidence are strong.
Tennessee and Kentucky have substantial orthopedic-care ecosystems and elevated chronic musculoskeletal burden, creating demand for knee, spine, foot, and ankle devices. West Virginia, Alabama, Mississippi, Arkansas, Louisiana, and Oklahoma have comparatively high obesity, diabetes, inactivity, and chronic disease prevalence, increasing clinical need even where rural access limits specialist capacity.
For manufacturers, this creates a two-track Southern strategy. High-growth metropolitan markets support premium sports, postoperative, and digitally customized products, while rural and chronic-disease markets require accessible lower-limb, spinal, and mobility-oriented solutions supported by efficient DME distribution.
The South is expected to increase its share modestly through 2032 and could approach USD 0.98 billion by the end of the forecast period as Texas, Florida, Georgia, North Carolina, Tennessee, and other high-growth states continue expanding.
West
The West accounts for approximately 24% of U.S. market value, or USD 0.43 billion in 2026, and is expected to record the strongest technology-driven growth through 2032. The region includes California, Washington, Oregon, Nevada, Arizona, Utah, Idaho, Montana, Wyoming, Colorado, New Mexico, Alaska, and Hawaii.
California is the dominant Western market. With approximately 39.36 million residents in 2025, it remains the largest U.S. state by population and supports major orthopedic, rehabilitation, pediatric, academic, sports-medicine, and digital-health ecosystems. Los Angeles, San Diego, the Bay Area, Sacramento, and Inland Empire markets create a diverse customer base ranging from high-acuity academic centers to large orthopedic groups and consumer health channels.
California is particularly well positioned for digitally scanned orthoses, additive manufacturing, connected rehabilitation, premium sports bracing, and patient-specific products. Its large Medicaid population also creates an important contrast between premium technology adoption and payer-sensitive public-sector procurement.
Arizona and Nevada are high-growth markets because of population migration and aging. Arizona’s population surpassed 7.6 million in 2025, and the Phoenix metropolitan region has become a major orthopedic and rehabilitation hub. Older-adult growth is commercially important for knee OA, spinal, gait, foot, and postoperative orthoses.
Colorado and Utah are attractive for sports and performance-related orthotics because of active populations, while their integrated provider networks support advanced orthopedic care. These states also provide favorable environments for high-performance ankle, knee, and foot systems.
Washington and Oregon combine major integrated delivery networks with high adoption of digital health and evidence-driven clinical pathways. This favors orthotic vendors able to connect device selection with rehabilitation outcomes rather than competing as stand-alone brace suppliers.
New Mexico, Idaho, Montana, Wyoming, Alaska, and Hawaii are smaller state markets but present distinctive access challenges. Rural distances and specialist shortages can make rapid fitting, remote evaluation, digital scanning, and centralized fabrication particularly valuable.
The West is projected to move toward approximately 25% of the national market by 2032, representing a value pool approaching USD 0.66 billion. Growth will be led by California, Arizona, Washington, Colorado, Utah, and Nevada.
Northeast
The Northeast represents approximately 21% of market revenue, or USD 0.37 billion in 2026. The region comprises Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania.
The Northeast is characterized by dense healthcare infrastructure, high physician and therapist concentration, leading children’s hospitals, advanced rehabilitation institutions, academic orthopedic programs, and relatively strong commercial insurance penetration. These factors support premium orthotic adoption despite slower population growth compared with the South and West.
New York, with approximately 20 million residents in 2025, is the region’s largest state market. New York City and surrounding metropolitan areas support significant demand across orthopedic surgery, trauma, rehabilitation, sports medicine, pediatrics, neurology, and podiatry. Upstate markets add a substantial Medicare and chronic-disease population.
Pennsylvania, at more than 13 million residents, is another major market. Philadelphia and Pittsburgh contain sophisticated orthopedic and rehabilitation ecosystems, while the state’s large older population supports chronic knee, spinal, foot, and gait-related orthotics.
New Jersey, with more than 9.5 million residents, benefits from dense outpatient care networks, proximity to New York and Philadelphia medical markets, and high commercial payer exposure.
Massachusetts has an outsized strategic role because Boston’s academic hospitals, rehabilitation institutions, clinical-research centers, engineering ecosystem, and digital-health companies frequently influence adoption of advanced medical technologies. Although smaller in total volume than New York, it is particularly relevant for pediatric orthotics, neurological rehabilitation, complex gait management, and digitally customized devices.
Connecticut, Rhode Island, Maine, New Hampshire, and Vermont provide smaller but clinically important markets. Aging populations in northern New England support OA, spinal, gait, and foot orthotics, while rural access creates opportunities for remote fitting and efficient regional fabrication networks.
The Northeast is unlikely to match the South or West in absolute growth, but it should remain one of the strongest markets for high-value customized devices and evidence-based orthotic care. The region could approach USD 0.53 billion by 2032.
Midwest
The Midwest accounts for approximately 19% of the U.S. market, or USD 0.34 billion in 2026. The region includes Ohio, Indiana, Illinois, Michigan, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota.
The market is supported by established orthopedic service lines, large community hospital systems, major rehabilitation networks, high sports participation, manufacturing employment, aging communities, and a substantial chronic musculoskeletal disease burden.
Illinois, with approximately 12.7 million residents in 2025, is the region’s largest market. Chicago supports major academic hospitals, children’s institutions, sports-medicine programs, rehabilitation centers, and specialist orthotic providers.
Ohio, with approximately 11.9 million residents, has one of the country’s most developed orthopedic and rehabilitation infrastructures. Cleveland, Columbus, and Cincinnati support large referral populations and high-value clinical orthotics.
Michigan, at approximately 10.1 million residents, combines metropolitan orthopedic demand with a large industrial and occupational-health base. Knee, ankle, hand, wrist, and spine products have relevance across both chronic disease and injury.
Minnesota is strategically important beyond its population because of its medical-device ecosystem and highly organized care systems. Advanced orthotic technology, digital fabrication, and evidence-based procurement can gain traction through sophisticated regional providers.
Wisconsin, Indiana, Missouri, Iowa, and Kansas provide stable demand across orthopedic clinics, rehabilitation centers, sports medicine, and Medicare populations. Nebraska, North Dakota, and South Dakota are smaller markets where rural access, telehealth, centralized fabrication, and regional referral networks influence orthotic distribution.
Obesity prevalence in the Midwest reached approximately 35.9% in 2024, the highest among the four major U.S. regions. This creates long-term pressure on knee, ankle, foot, and spinal conditions and provides a durable underlying demand base for conservative musculoskeletal intervention.
The Midwest is expected to remain relatively stable in national share, reaching approximately USD 0.47 billion by 2032. Manufacturers will generally compete successfully through clinical education, dependable service, payer support, and strong relationships with integrated provider networks rather than through consumer branding alone.
Key Market Players
The U.S. Orthotic Devices Competitive Landscape is moderately fragmented. Several multinational mobility and orthopedic companies compete alongside specialized U.S. bracing manufacturers, custom orthotics companies, spinal-bracing specialists, and family-owned clinical-device firms.
Competition occurs across five principal dimensions: biomechanical performance, comfort and adherence, clinician familiarity, reimbursement and documentation support, and distribution reach. Custom-fabricated and highly technical orthoses create stronger barriers to entry than commodity elastic supports, while digital scanning and design capabilities are beginning to differentiate manufacturers in patient-specific markets.
Some of the highly relevant participants in the U.S. Orthotic Devices industry are:
Enovis Corporation / DJO / DonJoy
Össur / Össur Americas
Ottobock
Breg, Inc.
Aspen Medical Products
Bauerfeind USA
medi USA
Thuasne USA
DeRoyal Industries
Hely & Weber
Orthomerica Products
Becker Orthopedic
Allard USA
Spinal Technology, Inc.
Trulife
Enovis has one of the broadest U.S. bracing portfolios through DonJoy and related brands, with strong exposure to knee, sports medicine, postoperative, spine, ankle, and rehabilitation. Össur and Ottobock bring substantial biomechanical expertise and global scale, particularly in advanced lower-limb orthotics and mobility. Breg is deeply embedded in U.S. orthopedic and postoperative bracing workflows, while Aspen Medical Products holds a strong position in spinal support.
Bauerfeind, medi, and Thuasne compete through clinically differentiated supports and European engineering adapted to the U.S. market. DeRoyal, Hely & Weber, Orthomerica, Becker, Allard, Spinal Technology, and Trulife provide meaningful competition in specialized upper-limb, lower-limb, pediatric, spinal, rehabilitation, and custom-fabricated categories.
Competitive share through 2032 will be influenced less by portfolio breadth alone and more by the ability to integrate prescribing, fitting, documentation, fabrication, inventory, and follow-up. Manufacturers capable of reducing administrative friction for orthopedic practices and DME suppliers should gain disproportionate loyalty.
Recent Developments
One of the most notable 2026 product developments was Enovis’ launch of the DonJoy Spinamic Hybrid Scoliosis Brace in the United States. The device combines rigid corrective elements with a breathable, adjustable configuration and is available in ten off-the-shelf sizes. Its significance extends beyond product design because it illustrates how orthotic manufacturers are attempting to shorten the conventional gap between individualized correction and ready-to-fit inventory.
Medicare policy is also becoming a more important competitive factor. CMS continued expanding payment-condition requirements for DMEPOS products in 2026, including additional orthotic codes within prior-authorization and related compliance frameworks. Certain upper-limb orthoses are being brought into phased prior-authorization implementation beginning in selected states before national expansion. These developments increase the value of documentation-ready manufacturers and distributors.
The DMEPOS competitive-bidding environment remains relevant. Contracts covering off-the-shelf back and knee braces under the earlier competitive-bidding round expired at the end of 2023, with a temporary gap period beginning in January 2024. Future bidding reforms and pricing mechanisms remain important variables for suppliers with substantial Medicare exposure.
FDA regulation remains comparatively favorable for many conventional devices. External knee, ankle, hip, and other limb braces can fall within Class I orthosis classifications, and several common categories are exempt from 510(k) premarket notification. The result is a market where product iteration can occur more rapidly than in implantable orthopedics, increasing competition around materials, patient comfort, digital workflows, and clinical positioning.
Digital manufacturing continues to progress across the sector. Orthotists are expanding use of optical scanning, CAD-based rectification, digitally stored patient files, CNC milling, and additive manufacturing. These technologies are particularly important for custom AFOs, pediatric orthotics, foot orthoses, and complex patient anatomies.
Hospital and orthopedic-group procurement is also changing. Providers increasingly favor fewer vendors capable of covering multiple anatomical categories while supporting product education, fit protocols, billing pathways, and inventory management. This creates a strategic advantage for companies with broad clinical portfolios, but specialized manufacturers can retain strong positions where their devices produce superior functional outcomes or solve difficult fitting problems.
Conclusion
The U.S. Orthotic Devices Market Size & Share is positioned to expand from USD 1.78 billion in 2026 to approximately USD 2.64 billion by 2032, representing a 6.79% CAGR during 2027–2032. Historical market value increased from approximately USD 1.42 billion in 2023 to USD 1.53 billion in 2024 and USD 1.66 billion in 2025, establishing a strong base for continued growth.
The market’s long-term attractiveness is grounded in structural healthcare needs rather than a single technology cycle. More than one-fifth of U.S. adults live with diagnosed arthritis, approximately 33 million adults have osteoarthritis, nearly half of adults aged 65 and above have diagnosed arthritis, and the older population now exceeds 61 million. Sports injuries, ankle sprains, postoperative orthopedic rehabilitation, chronic pain, neurological gait disorders, pediatric conditions, diabetes, and fall risk further diversify demand.
Knee orthoses will remain the largest product segment, while ankle-foot orthoses and digitally customized devices should be among the most strategically attractive growth categories. Prefabricated braces will continue to dominate unit volume, but custom-fabricated products are positioned to capture increasing value as digital scanning and advanced manufacturing improve efficiency.
The most important commercial transition through 2032 will be from selling a physical brace to delivering a complete orthotic-care workflow. U.S. clinicians and health systems increasingly need products that are clinically effective, comfortable enough to drive adherence, simple to fit, easy to document, compatible with reimbursement, and available without avoidable supply delays.
Regionally, the South will remain the largest opportunity, supported by Texas, Florida, Georgia, North Carolina, Virginia, and Tennessee. The West will provide the strongest innovation-led expansion, particularly in California, Arizona, Washington, Colorado, Utah, and Nevada. The Northeast will remain a premium clinical and academic market, while the Midwest will provide durable demand driven by established orthopedic infrastructure, elevated obesity prevalence, sports participation, and chronic musculoskeletal disease.
For clients evaluating the U.S. Orthotic Devices Market, the central strategic issue is not simply whether demand for braces and orthoses will increase. The more commercially relevant questions are which product categories can command value above commodity supports, how rapidly custom fabrication can be digitized, which channels can dispense devices with the least reimbursement friction, and which manufacturers can convert biomechanical innovation into measurable patient adherence and functional outcomes.
Companies that align product design with clinical workflow economics, reimbursement compliance, patient comfort, rapid fulfillment, and evidence-based orthopedic care will be best positioned to capture the next phase of U.S. market growth.